tbuckley/cabot-search huggingface dataset:
Abstract 9174: Integration of Nonlinear Analysis and Artificial Intelligence for Human Ipsc-based Drug Cardiotoxicity Classification
Authors: Zhen Ma, Andrew Kowalczewski
Journal: Circulation (2021)

Introduction: Recent advances in human induced pluripotent stem cell ( hiPSC ) technology have granted novel tools to evaluate drug-induced cardiotoxicity on human cardiomyocytes. The contractile signals recorded from hiPSC-derived cardiomyocytes ( hiPSC-CMs ) are highly complex and dynamic with great degree of characteristics to various drug treatment. However, traditional linear methods often fail to capture the subtle variations in these signals generated by hiPSC-CMs. In this work, we integrated nonlinear analysis, dimensionality reduction techniques and machine learning algorithms for better classifying the contractile signals from hiPSC-CMs in response to different drug exposure. Methods: Beating hiPSC-CMs were treated with different drugs and analyzed based on contractile motions and calcium flux. Nonlinear analysis was used to compute the dimensional properties. All the contractile parameters are incorporated in different machine learning algorithms to detect the variations in contractile behaviors that reflect cardiotoxic effects. The visualization of drug treatment and dosages were accomplished utilizing dimensionality reduction techniques, t-distributed stochastic neighbor embedding (t-SNE). Results: Machine learning algorithms combined with nonlinear analysis proved far more sensitive to the changes in contractile functions than when using traditional linear analysis alone. Using Radom Forest algorithm, classification between drug-treatment and baseline control showed an accuracy higher than 96% with the inclusion of nonlinear parameters. Higher dimensional relations between variables and treatment groups were successfully visualized utilizing t-SNE to gain further insights of each drug. Conclusions: Integration of nonlinear analysis and artificial intelligence has proven to be a powerful tool for analyzing cardiotoxicity and classifying toxic compounds through their mechanistic action.
Single Cord Blood Transplantation Versus HLA-Haploidentical Related Donor Transplantation Using Post-Transplant Cyclophosphamide in Patients with Hematological Malignancies
Authors: Fumiya Wada, Junya Kanda, Satoshi Yoshioka, Takayuki Ishikawa, Takashi Akasaka, Yasunori Ueda, Hirokazu Hirata, Yasuyuki Arai, Kazuhiro Yago, Naoyuki Anzai, Mitsumasa Watanabe, Takashi Ikeda, Akihito Yonezawa, Kazunori Imada, Mitsuru Itoh, Toshiyuki Kitano, Tomoharu Takeoka, Masakatsu Hishizawa, Masaharu Nohgawa, Nobuyoshi Arima, Kosuke Asagoe, Tadakazu Kondo, Akifumi Takaori-Kondo
Journal: Blood (2021)
Acute respiratory illness and return to sport: a systematic review and meta-analysis by a subgroup of the IOC consensus on ‘acute respiratory illness in the athlete’
Authors: Carolette Snyders, David B Pyne, Nicola Sewry, James H Hull, Kelly Kaulback, Martin Schwellnus
Journal: British Journal of Sports Medicine (2021)

Objective To determine the days until return to sport (RTS) after acute respiratory illness (ARill), frequency of time loss after ARill resulting in &gt;1 day lost from training/competition, and symptom duration (days) of ARill in athletes. Design Systematic review and meta-analysis. Data sources PubMed, EBSCOhost, Web of Science, January 1990–July 2020. Eligibility criteria Original research articles published in English on athletes/military recruits (15–65 years) with symptoms/diagnosis of an ARill and reporting any of the following: days until RTS after ARill, frequency (%) of time loss &gt;1 day after ARill or symptom duration (days) of ARill. Results 767 articles were identified; 54 were included (n=31 065 athletes). 4 studies reported days until RTS (range: 0–8.5 days). Frequency (%) of time loss &gt;1 day after ARill was 20.4% (95% CI 15.3% to 25.4%). The mean symptom duration for all ARill was 7.1 days (95% CI 6.2 to 8.0). Results were similar between subgroups: pathological classification (acute respiratory infection (ARinf) vs undiagnosed ARill), anatomical classification (upper vs general ARill) or diagnostic method of ARinf (symptoms, physical examination, special investigations identifying pathogens). Conclusions In 80% of ARill in athletes, no days were lost from training/competition. The mean duration of ARill symptoms in athletes was 7 days. Outcomes were not influenced by pathological or anatomical classification of ARill, or in ARinf diagnosed by various methods. Current data are limited, and future studies with standardised approaches to definitions, diagnostic methods and classifications of ARill are needed to obtain detailed clinical, laboratory and specific pathogen data to inform RTS. PROSPERO registration number CRD42020160479.
Abstract 9536: Prediction of Drug-Induced QTc Prolongation With an ECG Based Machine Learning Model
Authors: Thomas Morland, Sushravya Raghunath, Christopher R Kelsey, Jeffrey Ruhl, Steven R Steinhubl, Mariya P Monfette, John Pfeifer, Ruijun Chen, Noah Zimmerman, Brian P Delisle, Randle Storm, Christopher M Haggerty, Brandon Fornwalt
Journal: Circulation (2021)

Introduction: Initiation of QTc-prolonging medications may lead to the rare but potentially catastrophic event, torsades de pointes (TDP). At present, no adequate, generalizable tools exist to predict drug-induced long QTc (LQT); machine learning from ECG data is a promising approach. Hypothesis: Prediction of drug-induced LQT using an ECG-based machine learning model is feasible, and outperforms a model trained on baseline QTc, age, and sex alone. Methods: We identified baseline 12-lead ECGs with QTc values &lt; 500 ms for patients who had not received any known, conditional, or possible QTc prolonging medication per CredibleMeds at the time of ECG or within the past 90 days. We matched these with ECGs from the same patients while they were taking at least one CredibleMeds drug (“on-drug” ECGs). Using 5-fold cross-validation, we trained and tested two machine learning models using the baseline ECGs of the 92,848 resulting pairs to predict drug-induced LQT (≥500 ms) in the on-drug ECGs: a deep neural network using ECG voltage data, and a gradient-boosted tree using the baseline QTc. Age and sex were also inputs to both models. Results: On-drug LQT prevalence was 16%. The ECG model demonstrated superior performance in predicting on-drug LQT (area under the receiver operating characteristic curve (AUC) = 0.756) compared to the QTc model (0.710). At a potential operating point (Figure), the ECG model had 89% sensitivity and 95% negative predictive value. Even in the subset of patients with baseline QTc &lt; 470/480 ms (male/female; post-drug LQT prevalence = 14%), the ECG model demonstrated good performance (AUC = 0.736). Conclusions: An ECG-based machine learning model can stratify patients by risk of developing drug-induced LQT better than a model using baseline QTc alone. This model may have clinical value to identify high-risk drug starts that would benefit from closer monitoring and others who are at low risk of drug-induced LQT.
Abstract 177: Obesity promotes growth of ovarian cancer through adipose stem cells
Authors: Yan Zhang, Travis Solley, Karen Lu, Caimiao Wei, Alesandra Nowicka, Ann Klopp
Journal: Cancer Research (2014)

Abstract Introduction: Intraperitoneal spread to visceral adipose is a frequent event and a major cause of morbidity and mortality in women with ovarian cancer. Excess visceral adiposity increases the risk of ovarian cancer. We hypothesized that obesity effects may be mediated by the adipose-derived stem cell population (ASC) to enhance the initiation and progression of ovarian cancer. Results: Intraperitoneally injected ID8 ovarian cancer cells grew significantly faster in mice with diet-induced obesity (p&amp;lt;0.05). To determine if ASC mediated this effect, ASC were then isolated from the subcutaneous (SC-ASC) and visceral adipose (V-ASC) of mice with diet-induced obesity and lean mice. ASC from all sources expressed same mesenchymal cell surface markers and similarly increased ID8 cell proliferation and survival following paclitaxel treatment. There was no significant difference in ID8 migration in response to ASC conditioned media from lean and obese mice. ASC from obese mice exhibited impaired differentiation into adipocytes and osteocytes in-vitro as compared to ASC from lean mice. 106 renilla luciferase expressing ID8 were co-injected intra-peritoneally with equal number of different ASC isolates into C57Bl6 mice. SC-ASC from obese mice promoted growth of intraperitoneal tumor and the formation of metastasis as compared to SC-ASC from lean mice (p&amp;lt;0.05). There was no significant difference in the effect of V-ASCs from obese and lean mice on ID8 cells. There was trend towards more rapid tumor growth in mice injected with V-ASC as compared to SC-ASC from lean mice. Ascites volume was highest in mice injected with SC-ASC derived from obese mice. SC-ASC from obese mice increased tumor vascularity while ASC from obese mice increased the formation of intra-tumoral perilipin expressing adipocytes. Conclusions: SC-ASC from obese mice promoted tumor growth more than ASC from lean mice suggesting that obesity alters the ASC population to enhance tumor-promoting effects. Obese derived ASC exhibit impaired differentiation potential, which may be linked to tumor promoting effects. Future studies will focus on understanding the mechanisms by which obesity alters the ASC population to impact tumor progression. Citation Format: Yan Zhang, Travis Solley, Karen Lu, Caimiao Wei, Alesandra Nowicka, Ann Klopp. Obesity promotes growth of ovarian cancer through adipose stem cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 177. doi:10.1158/1538-7445.AM2014-177
A Novel Approach to Induce ATRA Mediated Differentiation in NPM1 Mutant Acute Myeloid Leukemia
Authors: Metis Hasipek, Yihong Guan, Dale Grabowski, Xiaorong Gu, Jaroslaw P. Maciejewski, Yogenthiran Saunthararajah, Hetty E. Carraway, Babal K. Jha
Journal: Blood (2021)
Abstract 8905: Cardiac Troponin Thresholds and Kinetics to Differentiate Myocardial Injury and Myocardial Infarction
Authors: Ryan Wereski, Dorien Kimenai, Caelan Taggart, Dimitrios Doudesis, Kuan Ken Lee, Mathew T Lowry, Anda Bularga, David Lowe, Takeshi Fujisawa, Fred S Apple, Paul O Collinson, Atul Anand, Andrew Chapman, Nicholas L Mills
Journal: Circulation (2021)

Background: Whilst the 99th percentile is the recommended diagnostic threshold for myocardial infarction (MI), some guidelines also advocate the use of higher troponin thresholds to rule-in MI at presentation. It is unclear whether the magnitude or change in troponin concentration can differentiate causes of myocardial injury and infarction in practice. Hypothesis: Troponin concentration alone cannot to distinguish subtypes of myocardial infarction Methods: In a secondary analysis of a multi-centre randomized controlled trial, we identified 46,092 consecutive patients presenting with suspected acute coronary syndrome without STEMI. High-sensitivity troponin I concentrations at presentation and on serial testing were evaluated. The positive predictive value (PPV) and specificity were determined at the sex-specific 99th percentile upper reference limit (URL), and rule-in thresholds of 64 ng/L and 5-fold of the URL for a diagnosis of type 1 MI. Results: Troponin concentrations were similar at presentation in type 1 (median [IQR] 91 [30-493] ng/L) and type 2 MI (50 [22-147] ng/L), and in acute (50 [26-134] ng/L) and chronic (51 [31-130] ng/L) myocardial injury (Figure A). The 99th percentile and rule-in thresholds of 64 ng/L and 5-fold URL gave a PPV of 57% (95% confidence interval [CI] 56-58%), 59% (58-61%) and 62% (60-64%), and a specificity of 96% (96-96%), 96% (96-96%) and 98% (97-98%), respectively (Figure B). The absolute, relative and rate of change in troponin concentration was highest in patients with type 1 MI (P&lt;0.001 for all, Figure C). Discrimination improved when troponin concentration and change in troponin were combined compared to troponin concentration at presentation alone (area under curve, 0.661 versus 0.613). Conclusions: Troponin concentrations at presentation are insufficient to distinguish type 1 MI from other causes of myocardial injury or infarction in practice and should not guide management decisions in isolation.
Abstract 9035: Scavenger Receptor-BI: Implications in Lipoprotein(a) Metabolism
Authors: Mark S Kindy
Journal: Circulation (2021)

Introduction: Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for developing vascular disease and stroke. Hypothesis: We hypothesize that SR-BI is critical to the regulation of Lp(a) metabolism and that mutations in SR-BI contribute to the pathogenesis of CVD and stroke in relationship to Lp(a). Methods: Transgenic mice carrying the human Lp(a) [hLp(a)] on the SR-BI (mSR-BI) deficient mouse background, Lp(a) transgenic mice on the human SR-BI (hSR-BI) with and without the mSR-BI, and Lp(a) transgenic mice on the mutant hSR-BI with and without mSR-BI were used to determine the impact on Lp(a) catabolism and atherosclerosis. Results: We determined the levels of Lp(a) in wildtype and SR-BI KO mice, lipid levels and profiles and oxidized state of the Lp(a). In addition, studies on the impact of SR-BI and Lp(a) on atherosclerosis were examined. We showed that Lp(a) was elevated in SR-BI deficient mice and Lp(a) was reduced in hSR-BI tg mice, compared to wildtype SR-BI mice. Lp(a) mice with the mutant hSR-BI protein, showed significantly elevated Lp(a) levels. When Lp(a) levels were increased, Lp(a) was highly oxidized, lipid profiles were altered and mice develop significant atherosclerosis. We also showed that Lp(a) mice showed a higher incidence of hemorrhagic strokes and had worse outcomes following ischemic strokes. Conclusions: These studies will lay the ground work for both basic and translational studies to understand the impact of Lp(a) in CVD and stroke.
Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Authors: Nicholas J. Short, Hagop Kantarjian, Farhad Ravandi, Xuelin Huang, Nitin Jain, Tapan M. Kadia, Joseph D. Khoury, Jeffrey L. Jorgensen, Sa A Wang, Yesid Alvarado, Jan A. Burger, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Marina Konopleva, Naveen Pemmaraju, Guillermo Garcia-Manero, William G. Wierda, Steven M. Kornblau, Jovitta Jacob, Monica Kwari, Caitlin R. Rausch, Christopher Loiselle, Anna Milton, Juan Rivera, Rebecca Garris, Susan M. O'Brien, Elias J. Jabbour
Journal: Blood (2021)
Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)
Authors: John E. Godwin, Bassam Mattar, Michael Maris, Carlos Bachier, Don Stevens, Daanish Hoda, Juan C. Varela, Mohamad Cherry, Suzanne Fanning, James Essell, Habte Yimer, Jay Courtright, Jeff P. Sharman, Ricardo Espinola, Connor Mailley, Ariel Avilion, Ken Ogasawara, San-San Ou, Paul Shaughnessy
Journal: Blood (2021)
Race-Ethnic Enrollment Disparities over 15 Years of Alliance/CALGB Acute Myeloid Leukemia Clinical Trials, Biobanks, and Correlative Science Protocols
Authors: Andrew Hantel, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, Wendy Stock, Sawyer Jacobson, Sumithra J Mandrekar, Richard M. Stone, Daniel J. DeAngelo, John C. Byrd, Gregory A. Abel
Journal: Blood (2021)
Characterizing Iron Overload By Age in Patients Diagnosed with Pyruvate Kinase Deficiency - a Descriptive Analysis from the Peak Registry
Authors: Paola Bianchi, Rachael F. Grace, Joan-Lluis Vives Corrons, Bert Glader, Andreas Glenthøj, Hitoshi Kanno, Kevin H.M. Kuo, Carl Lander, D. Mark Layton, Dagmar Pospíŝilová, Vip Viprakasit, Jean Williams, Yan Yan, Bryan McGee, Eduard J. Van Beers
Journal: Blood (2021)
Safety and Efficacy of Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL)
Authors: Michael Wang, Tadeusz Robak, Kami J. Maddocks, Tycel Phillips, Stephen D. Smith, David Gallinson, Roser Calvo, Chuan-Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak
Journal: Blood (2021)
The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice
Authors: Xavier Leleu, Mario Boccadoro, Hans C. Lee, Jeffrey A. Zonder, Magaret Macro, Karthik Ramasamy, Cyrille Hulin, Jiri Silar, Matyáš Kuhn, Kaili Ren, Nawal Bent-Ennakhil, Sylvie Bouillie, Dasha Cherepanov, Dawn Marie Stull, Evangelos Terpos
Journal: Blood (2021)
<i>Bacterial Prophylaxis in Patients with Acute Gvhd; Who Is at Risk for Bloodstream Infections?</i>
Authors: Whitney Wallis, Alison Gulbis, Tao Wang, Karen Chen, Carrie Lynn Kitko, Margaret L. MacMillan, Joseph Pidala, Marcie L. Riches, Stephen R. Spellman, Mukta Arora, Amin M. Alousi
Journal: Blood (2021)
Diversity, Equity, and Inclusion in Hematology and Oncology Fellowship Programs
Authors: Michael Mankbadi, Lidet Alemu, Afiya Bey, Nathan T. Connell, Lisa Fanning, Patricia Frustace, Inginia Genao, Janet Hafler, Ann S. LaCasce, Tiffany Lin Lucas, Ariela L. Marshall, Jodi Mones, Martina C Murphy, Rakhi P. Naik, Nikolai Podoltsev, Alfred Ian Lee
Journal: Blood (2021)
High molecular weight hyper-branched PCL-based thermogelling vitreous endotamponades
Authors: Qianyu Lin, Zengping Liu, Daniel S.L. Wong, Chen Chuan Lim, Connie K. Liu, Liangfeng Guo, Xinxin Zhao, Yi Jian Boo, Joey H.M. Wong, Rebekah P.T. Tan, Kun Xue, Jason Y.C. Lim, Xinyi Su, Xian Jun Loh
Journal: Biomaterials (2021)
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Barry Paul, Michaela Liedtke, Jorge Monge, Maria Chaudhry, Robert M. Rifkin, Mitul D. Gandhi, Jack Khouri, Andrew Kin, Tibor Kovacsovics, Moshe Y. Levy, Ann Mohrbacher, William Schmidt, David S. Siegel, Rebecca W. Silbermann, Anna Louise Byrne, Tina Ncube, Michael Murphy, Lin Gu, Nishanthan Rajakumaraswamy, Mark Chao, Saad Z. Usmani
Journal: Blood (2021)
Categorized Hematologic Response to Pegcetacoplan and Correlations with Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis of Data from Phase 1b, Phase 2a, and Phase 3 Trials
Authors: Antonio Risitano, Raymond S Wong, Mohammed Al-Adhami, Crystal Chen, Regis Peffault De Latour
Journal: Blood (2021)
The Impact of the COVID-19 Pandemic on Quality of Life in Danish Patients with Multiple Myeloma; Results from an Ongoing Longitudinal National Survey
Authors: Louise Redder, Sören Möller, Anna Thit Johnsen, Mary Jarden, Christen lykkegaard Andersen, Henrik Frederiksen, Henrik Gregersen, Anja Klostergaard, Morten Saaby Steffensen, Per Troellund Pedersen, Maja Hinge, Mikael Frederiksen, Carsten Helleberg, Niels Abildgaard, Lene Kongsgaard Nielsen
Journal: Blood (2021)
Abstract 11426: Signs of Depression Predict Mortality Among Swedish Heart Failure Patients
Authors: Hannes Holmes, John Molvin, Johan Korduner, Amra Jujic, Erasmus Bachus, Martin Magnusson
Journal: Circulation (2021)

Introduction: Anxiety and depression are common comorbid conditions in heart failure (HF), and there is growing evidence that they increase the risk of adverse outcomes, including rehospitalization and functional decline. Hypothesis: We aimed to determine if symptoms of anxiety and depression would predict mortality and rehospitalization in a Swedish prospective HF patient cohort. Methods: 387 patients hospitalized for HF (mean age 75 years; 32% women) were assessed using the Hospital Anxiety and Depression Scale (HADS) to measure symptoms of anxiety (HADS Anxiety) and depression (HADS Depression). The median follow-up time to death and rehospitalization was 665 (range,1737; interquartile range, 811) and 316 (range, 2069; interquartile range, 348) days, respectively. Relations between baseline HADS scores, mortality and rehospitalization risk were analyzed using multivariable Cox regression analysis adjusted for age, sex, body- mass index, smoking, prevalent atrial fibrillation, educational level, prevalent diabetes, NYHA-class at hospitalization and systolic blood pressure. Results: A total of 30 patients (8%) had signs of depression according to HADS Depression score &gt;11 points. In the fully adjusted Cox regression model using continuous standardized values per 1 SD change, higher score on HADS Depression scale (HR,1.42; CI, 1.16-1.75; p=0.001) yielded significant associations with increased mortality whereas no associations were found for HADS Anxiety scale (HR, 1.04; CI, 0.86-1.26; p=0.719). Rehospitalization risk (n = 246; 64%) was not significantly associated with higher scores on HADS Depression scale (HR, 1.08; CI, 0.94-1.25; p=0.274) or HADS Anxiety scale (HR, 0.95; CI, 0.82-1.09; p=0.449). Conclusions: Higher scores on HADS Depression scale indicated increased mortality risk in hospitalized HF patients, independently of traditional risk factors. However, higher scores on HADS Anxiety scale did not herald increased risk of mortality or rehospitalization.
Clinically Important Difference for the FACIT-Fatigue Scale in Paroxysmal Nocturnal Hemoglobinuria: A Derivation from International PNH Registry Patient Data
Authors: David Cella, Peter Johansson, Yasutaka Ueda, Ioannis Tomazos, Philippe Gustovic, Alice Wang, Ami S. Patel, Hubert Schrezenmeier
Journal: Blood (2021)
Ex Vivo T-Cell Receptor αβ +/CD19 +depletion of Peripheral Stem Cell Grafts for Pediatric Patients with Bone Marrow Failure (BMF) Undergoing Unrelated Donor Transplantation
Authors: Joseph H Oved, Caitlin W Elgarten, Yongping Wang, Stephan Kadauke, Dimitri S. Monos, David M. Barrett, Stephan A. Grupp, Nancy Bunin, Timothy S. Olson
Journal: Blood (2021)
Surveillance and outbreak reports
Authors: S Atkin, S Anaraki, P Gothard, A Walsh, D Brown, R Gopal, D Morgan, F Gobbi, G Napoletano, C Piovesan, F Russo, A Angheben, A Rossanese, L Gallo, M Valsecchi, A Piazza, G Venturi, Z Bisoffi, T Bruun, G Sørensen, T Jensen, K Nygard, G Kapperud, L Müller, C Kjelsø, M Hjertqvist, S Ethelberg, Y Guillois-Bécel, E Couturier, JC Le Saux, A Briand, C Robert, E Dussaix, M Pommepuy, V Vaillant
Journal: Eurosurveillance (2009)
Characteristics, Treatment and Outcome of 15 to 18 Years-Old Adolescents with Chronic Myeloid Leukemia (CML): The Experience of the International Registry of Childhood CML (I-CML-Ped Study)
Authors: Morgane Froment, Meinolf Suttorp, Stéphanie Ragot, Hélène Deutsch, Violaine Goyeau, Barbara De Moerloose, Silvia Regina Brandalise, Marina Borisevich, Petr Sedlacek, Adalet Meral Gunes, Birgitte Lausen, Antonio Molines Honrubia, Gordana Jakovljevic, Birgitta Versluys, Krzysztof Kalwak, Andrea Hraskova, Frederic Millot
Journal: Blood (2021)
Association of Single-blind Placebo Run-in Periods With the Placebo Response in Randomized Clinical Trials of Antidepressants
Authors: Amelia J. Scott, Louise Sharpe, Veronica Quinn, Ben Colagiuri
Journal: JAMA Psychiatry (2021)

Single-blind placebo run-in (PRI) periods are common in randomized clinical trials (RCTs) of treatment for depression. They aim to increase sensitivity to detect drug effects; however, the association of PRI periods with study outcomes remains unclear. This is concerning given the costs of PRI periods to patients and investigators.